LONDON - Vernalis plc completed a trilogy of deals, announcing an Hsp90 cancer research collaboration with the Novartis Institute for Biomedical Research to add to recent agreements with Biogen Idec Inc. and Endo Pharmaceuticals Inc. (BioWorld International)

Proteome Sciences Optimistic Following Setback With Biosite

Aug. 11, 2004

By Nuala Moran

Vernalis, Novartis Collaborate On Hsp90 Program In Cancer

Aug. 11, 2004

By Nuala Moran

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...